z-logo
Premium
Real‐world experience with leadless cardiac pacing
Author(s) -
Vaidya Vaibhav R.,
Dai Mingyan,
Asirvatham Samuel J.,
Rea Robert F.,
Thome Trena M.,
Srivathsan Komandoor,
Mulpuru Siva K.,
Kusumoto Fred,
Venkatachalam Kalpathi L.,
Ryan James D.,
Friedman Paul A.,
Cha YongMei
Publication year - 2019
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/pace.13601
Subject(s) - medicine , interquartile range , endocarditis , implant , surgery , tricuspid valve , cardiology
Background Leadless cardiac pacing (LCP) has emerged as a new modality for permanent pacing. We sought to describe comparative outcomes between LCP and transvenous pacemakers. Methods Patients receiving LCP (Micra [Medtronic, Minneapolis, MN, USA] and Nanostim [St. Jude Medical/Abbott Laboratories, Chicago, IL, USA]) between 2014 and 2017 at the Mayo Clinic Heart Rhythm Enterprise practice (Rochester, MN, USA; Jacksonville, FL, USA; and Scottsdale, AZ, USA) were identified. We identified 1:1 age‐ and sex‐matched controls receiving single‐chamber transvenous ventricular pacemakers (TVP). Statistical analyses were performed with JMP 13.0.0 (SAS, Institute Cary, NC, USA). Results Ninety patients underwent LCP implantation (73 Micra and 17 Nanostim) with a median follow‐up duration of 62 (interquartile range 28‐169) days. Both groups had 100% successful device implant rates. There were no differences in procedure‐related major (0% vs 1%) or minor complications (8% vs 3%) in the LCP versus TVP groups ( P  > 0.05). Excluding Nanostim patients, there was a lower rate of device‐related revision or extraction in the Micra versus TVP groups (0% vs 5%, P  = 0.028). Device endocarditis was more common in the TVP group (0% vs 3%, P  = 0.04). Estimated longevity was greater for the LCP group (median 12.0 vs 10.0 years, P  < 0.0001). An increase in severity of tricuspid valve regurgitation (TR) by ≥2 grades occurred in none of the LCP patients, and in 19% of the TVP patients ( P  = 0.017). Conclusion There are no significant differences in procedural complications among patients receiving LCP versus TVP. The Micra group had lower rates of device‐related revision/extraction compared to the TVP group. Patients with leadless pacemaker were less likely to develop endocarditis or worsening TR.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here